GTC Biotherapeutics to Host Third Quarter 2009 Earnings Call on November 6, 2009 and Webcast the Merriman Investor Summit Presentation on November 10, 2009
* Reuters is not responsible for the content in this press release.
http://www.businesswire.com/news/home/20091102006450/en
FRAMINGHAM, Mass.--(Business Wire)--
GTC Biotherapeutics, Inc. (Nasdaq: GTCB) ("GTC") announced today that its
financial results for the third quarter 2009 will be released on Friday,
November 6, 2009 followed by a webcast conference call starting at 10:00 a.m.
Eastern Time. You may access the live internet broadcast or the subsequent
archived recording, on GTC`s website at http://www.gtc-bio.com or access the
conference call as follows:
Live Call - In the United States, dial 1-877-407-0778
Outside the United States, dial 201-689-8565
Audio Archive - In the United States, dial 1-877-660-6853
Outside the United States, dial 201-612-7415
Reference call ID: Account #: 286 Conference ID #: 336816
NOTE: a replay of the call will be available one hour following the end of the
call and will be accessible until November 23, 2009 at 11:59 PM.
In addition, Geoffrey Cox, Ph.D., GTC`s Chairman and CEO, is scheduled to
present on Tuesday, November 10, 2009 at 10:40 a.m. during the Merriman Investor
Summit 2009. The conference is being held at the Sofitel Hotel in New York, New
York on November 10, 2009. More information about the conference can be found at
www.mdfco.com.
The presentation will be webcast live and can be accessed by logging onto
www.gtc-bio.com. The replay can be accessed from this same website and will be
available within 24 hours of the presentation.
About GTC Biotherapeutics
GTC Biotherapeutics develops, supplies and commercializes therapeutic proteins
produced through transgenic animal technology. ATryn®, GTC`s recombinant human
antithrombin, has been approved for use in the United States and Europe. ATryn
is the first and only product produced in transgenic animals to be approved for
therapeutic use anywhere in the world. In addition to ATryn, GTC is developing a
portfolio of recombinant human plasma proteins with known therapeutic
properties. These proteins include recombinant forms of human coagulation
factors VIIa and IX, which are being developed for the treatment of hemophilia.
GTC is also developing a portfolio of follow-on biologic monoclonal antibodies
and a CD20 antibody with enhanced ADCC (antibody-dependent cell-mediated
cytotoxicity). GTC`s intellectual property includes a patent in the United
States through 2021 for the production of any therapeutic protein in the milk of
any transgenic mammal. GTC`s transgenic production platform is particularly well
suited to enabling cost effective development of proteins that are difficult to
express in traditional recombinant production systems as well as proteins that
are required in large volumes. Additional information is available on the GTC
web site, http://www.gtc-bio.com.
GTC Biotherapeutics, Inc.
Thomas E. Newberry, 508-370-5374
Vice President, Corporate Communications
and Government Relations
tom.newberry@gtc-bio.com
Copyright Business Wire 2009
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters